Turkey

Sisecam: 3Q22 review – Better than expected results

  • Sisecam reported TL 4,801mn net income in 3Q22 which was 10% above our estimate of TL 4,384mn

  • The company’s EBITDA surged by 189% y/y to TL5,730mn in 3Q22, which was 2% higher than our estimate

  • The company generated 22.0% EBITDA margin in 3Q22, 48bps higher than our estimate of 21.5%

https://cdn.tellimer.com/providers/badge-ata-invest-bZ2qBXVWtZfl26qH3OLjfMn9TkdTsjoY6bSn27iv.png
Mustafa Bayram @ ATA Invest
November 1st, 2022
This is a premium report that requires access to ATA Invest
ATA Invest ATA Invest

Coverage

Turkey

About

ATA Holding is a third-generation family-owned conglomerate, primarily active in financial services, food & retail, technology and rea estate. ATA Group consists of more than 20 companies, with a total consolidated sales figure exceeding US$2.0bn.

Services

Personal solutions
Add-on
This includes investment consultancy, asset management, pension services, and more.
Corporate solutions
Add-on
We offer comprehensive services relating to mergers and acquisitions and privatisation products
Full list of services

Recommendations

Access to recommendations is a Pro feature.

Most Read

1 ∙ Strategy Note ∙ Global
Fixed income strategy: 2024 outlook – pick your battles
2 ∙ Strategy Note ∙ Global
6 lessons from EM Equities in 2023
3 ∙ Macro ∙ Pakistan
Pakistan IMF review sparks rally amid improved external trade and inflation
4 ∙ Macro ∙ Global
US rate cycles: How long do peak rates last?
5 ∙ Macro ∙ Global
Kenya to abandon Eurobond plan, Bank of Mauritius leaves rates unchanged

Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

This research is produced by a third party. The Tellimer team has had no editorial input into the content of the note.